JPMorgan Chase & Co. Sells 54,915 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

JPMorgan Chase & Co. trimmed its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 12.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 378,807 shares of the biopharmaceutical company’s stock after selling 54,915 shares during the period. JPMorgan Chase & Co.’s holdings in Catalyst Pharmaceuticals were worth $7,462,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Rothschild Investment LLC increased its position in shares of Catalyst Pharmaceuticals by 1,085.7% during the third quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,520 shares during the period. Advisory Services Network LLC purchased a new stake in Catalyst Pharmaceuticals in the third quarter worth about $39,000. Quarry LP bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $40,000. Financial Life Planners bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $42,000. Finally, Bessemer Group Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 331.4% during the 3rd quarter. Bessemer Group Inc. now owns 3,486 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 2,678 shares during the period. Institutional investors own 79.22% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CPRX. Citigroup increased their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Friday. Finally, Zacks Research raised Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Strong Buy” and a consensus target price of $34.00.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $23.78 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $26.58. The business has a fifty day moving average price of $24.04 and a 200-day moving average price of $22.74. The company has a market capitalization of $2.90 billion, a PE ratio of 14.07, a PEG ratio of 0.68 and a beta of 0.75.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).